The
metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1) is a bona fide
long noncoding RNA (
lncRNA).
LncRNA MALAT1 was discovered as a prognostic factor for
lung cancer metastasis but also has been linked to several other human
tumor entities. However, little is known about the role of
lncRNA MALAT1 in
glioma patients. The aim of this study was to identify the role of
lncRNA MALAT1 in the pathogenesis of
glioma; we analyzed the relationship of
lncRNA MALAT1 expression with clinicopathological characteristics in
glioma patients. In our results,
lncRNA MALAT1 expression was increased in
glioma tissues compared with paired adjacent brain normal tissues (P < 0.001). Furthermore,
lncRNA MALAT1 was associated significantly with WHO grade (I-II
vs. III-IV; P = 0.007) and
tumor size (< 3 cm vs. T ≥ 3 cm; P = 0.008). However,
lncRNA MALAT1 expression was not associated significantly with age (<45 vs. ≥ 45, P = 0.343), gender (female vs. male, P = 0.196), family history of
cancer (yes vs. no, P = 0.665), and
tumor location (supratentorial vs. infratentorial, P = 0.170). Moreover, the level of
lncRNA MALAT1 expression was markedly correlated with the
glioma patients' overall survival (P < 0.001). Multivariate analysis suggested that increased
lncRNA MALAT1 expression was a poor independent prognostic predictor for
glioma patients (P = 0.002). In conclusion,
lncRNA MALAT1 plays an important role on
glioma progression and prognosis and may serve as a convictive prognostic
biomarker for
glioma patients.